Unknown

Dataset Information

0

Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease.


ABSTRACT: Polypharmacy is common in patients with nonalcoholic fatty liver disease (NAFLD) and previous reports suggest that NAFLD is associated with altered drug disposition. This study aims to determine if patients with NAFLD are at risk for altered drug response by characterizing changes in hepatic mRNA expression of genes mediating drug disposition (pharmacogenes) across the histological NAFLD severity spectrum. We utilize RNA-seq for 93 liver biopsies with histologically staged NAFLD Activity Score (NAS), fibrosis stage, and steatohepatitis (NASH). We identify 37 significant pharmacogene-NAFLD severity associations including CYP2C19 downregulation. We chose to validate CYP2C19 due to its actionability in drug prescribing. Meta-analysis of 16 independent studies demonstrate that CYP2C19 is significantly downregulated to 46% in NASH, to 58% in high NAS, and to 43% in severe fibrosis. Our data demonstrate the downregulation of CYP2C19 in NAFLD which supports developing personalized medicine approaches for drugs sensitive to metabolism by the CYP2C19 enzyme.

SUBMITTER: Powell NR 

PROVIDER: S-EPMC10020163 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature

altmetric image

Publications

Clinically important alterations in pharmacogene expression in histologically severe nonalcoholic fatty liver disease.

Powell Nicholas R NR   Liang Tiebing T   Ipe Joseph J   Cao Sha S   Skaar Todd C TC   Desta Zeruesenay Z   Qian Hui-Rong HR   Ebert Philip J PJ   Chen Yu Y   Thomas Melissa K MK   Chalasani Naga N  

Nature communications 20230317 1


Polypharmacy is common in patients with nonalcoholic fatty liver disease (NAFLD) and previous reports suggest that NAFLD is associated with altered drug disposition. This study aims to determine if patients with NAFLD are at risk for altered drug response by characterizing changes in hepatic mRNA expression of genes mediating drug disposition (pharmacogenes) across the histological NAFLD severity spectrum. We utilize RNA-seq for 93 liver biopsies with histologically staged NAFLD Activity Score (  ...[more]

Similar Datasets

2023-02-27 | GSE225740 | GEO
| PRJNA937251 | ENA
| S-EPMC10835537 | biostudies-literature
| S-EPMC10008467 | biostudies-literature
| S-EPMC6019181 | biostudies-literature
| S-EPMC3982589 | biostudies-literature
| S-EPMC9583763 | biostudies-literature
| S-EPMC4491606 | biostudies-literature
| S-EPMC10282669 | biostudies-literature
| S-EPMC10446130 | biostudies-literature